LakeShore Biopharma (LSBCF) Company Report

Analyst Coverage

Research analysts covering LakeShore Biopharma.

Recent press releases and 8-K filings for LSBCF.

LakeShore Biopharma Postpones EGM After Buyer Group Claims Material Adverse Effect on Merger

LSBCF

M&A

Legal Proceedings

Takeover Bid

LakeShore Biopharma has received a notice from its Buyer Group asserting that recent arbitral awards, resulting in a financial liability of approximately RMB576,500,000, constitute a "Company Material Adverse Effect" under their merger agreement.
The Buyer Group claims the right to not consummate the going-private merger and will not attend or cast votes at the upcoming extraordinary general meeting (EGM).
As a result, LakeShore Biopharma has postponed the EGM, which was scheduled for February 12, 2026, to consider and vote on the merger proposal.
The Buyer Group has expressed willingness to engage in discussions to explore amendments to the transaction terms.

18 hours ago

LakeShore Biopharma Schedules EGM for Merger Vote

LSBCF

M&A

Delisting/Listing Issues

Proxy Vote Outcomes

LakeShore Biopharma Co., Ltd. will hold an Extraordinary General Meeting of Shareholders (EGM) on February 12, 2026, to vote on the Agreement and Plan of Merger dated November 4, 2025.
If the merger is consummated, LakeShore Biopharma will become a privately held company, and its ordinary shares (OTCPK: LSBCF) and warrants (OTCPK: LSBWF) will no longer be listed on any public market.
The company's board of directors has unanimously recommended that shareholders vote in favor of the merger agreement.
Shareholders of record as of January 16, 2026, are entitled to attend and vote at the EGM.

Jan 20, 2026, 12:43 PM

LakeShore Biopharma to hold Extraordinary General Meeting for merger vote

LSBCF

M&A

Delisting/Listing Issues

Proxy Vote

LakeShore Biopharma Co., Ltd will hold an Extraordinary General Meeting (EGM) on February 12, 2026, at 11 a.m. Beijing time.
The purpose of the EGM is to consider and vote on the previously announced Agreement and Plan of Merger dated November 4, 2025, with Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc..
If the merger is consummated, LakeShore Biopharma will become a privately held company, and its ordinary shares and warrants will no longer be listed on any public market or quotation system, including OTC Pink.
The Company's board of directors has recommended that shareholders vote FOR the proposal to authorize and approve the Merger Agreement and the transactions contemplated thereby.
Shareholders of record as of January 16, 2026, will be entitled to attend and vote at the EGM.

Jan 20, 2026, 12:00 PM

LakeShore Biopharma Enters Definitive Agreement for Going-Private Transaction

LSBCF

M&A

Delisting/Listing Issues

Takeover Bid

LakeShore Biopharma Co., Ltd. has entered into a definitive Merger Agreement with Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. for a going-private transaction.
The transaction implies an equity value of approximately US$37 million.
Each ordinary share will be cancelled in exchange for US$0.90 in cash per Share. This represents a premium of approximately 15.4% to the closing price on August 15, 2025, and 16.6% to the average closing price over the last 15 trading days prior to and including August 15, 2025.
The merger is expected to close during the first quarter of 2026 and will result in the company becoming privately held, with its shares no longer quoted on the OTC Pink Open Market. Rollover Shareholders, representing approximately 53.35% of the voting rights, have agreed to vote in favor of the merger.

Nov 4, 2025, 12:13 PM

LakeShore Biopharma Enters Definitive Agreement for Going-Private Transaction

LSBCF

M&A

Delisting/Listing Issues

Takeover Bid

LakeShore Biopharma (LSBCF) has entered into a definitive merger agreement with Oceanpine Skyline Inc. for a going-private transaction, implying an equity value of approximately US$37 million for the company.
Under the terms, each ordinary share will be cancelled in exchange for US$0.90 in cash, representing a 15.4% premium to the closing price on August 15, 2025.
The merger is expected to close during the first quarter of 2026 and will result in LakeShore Biopharma becoming a privately held company, with its shares no longer quoted on the OTC Pink Open Market.
Rollover Shareholders, holding approximately 53.35% of the voting rights, have agreed to vote in favor of the merger.

Nov 4, 2025, 12:04 PM

Get instant answers from SEC filings, earnings calls & more